All In Biotech

Drug Trial Radar · NCT05900986

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

An Open-label, Single-arm, Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of LS301-IT in Female Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for Ductal Carcinoma in Situ (DCIS) or Stage I-II Primary Invasive Breast Cancer

Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

22

Actual

Start

Jul 14, 2023

Primary completion

Oct 6, 2025

Study completion May 6, 2026

Sponsor

Lead sponsor
Integro TheranosticsIndustry
Sponsor type
Industry
First posted
Jun 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) injection in female patients undergoing partial mastectomy for DCIS (whether or not undergoing planned SLNB) or Stage I-II primary invasive breast cancer undergoing SLNB. Safety is the primary objective of this study, followed by efficacy that will be assessed from fluorescence imaging observations and data.

Conditions

  • Breast Cancer
  • DCIS
  • Invasive Duct Carcinoma of Breast

Interventions

  • LS301-IT 0.025 mg/kgDrug

    The dose of LS301-IT planned to be administered to the first cohort of patients is 0.025 mg/kg. Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased (by 50% as necessary). The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.

  • LS301-IT 0.05 mg/kgDrug

    Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.

  • LS301-IT 0.075 mg/kgDrug

    Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.

  • LS301-IT 0.1 mg/kgDrug

    Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: 30 days
  2. PharmacodynamicsTime frame: during surgery
  3. PharmacodynamicsTime frame: During surgery
  4. CmaxTime frame: 24 hours
  5. AUCinfTime frame: 24 hours
  6. AUClastTime frame: 24 hours
  7. TmaxTime frame: 24 hours
  8. t1/2Time frame: 24 hours

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Integro Theranostics Research Site #2

    Scottsdale, Arizona

  • Integro Theranostics Research Site #12

    Washington D.C., District of Columbia

  • Integro Theranostics Research Site #9

    Weston, Florida

  • Integro Theranostics Research Site #6

    The Bronx, New York

  • Integro Theranostics Clinical Research Site #8

    Winston-Salem, North Carolina

  • Integro Theranostics Research Site #10

    Cleveland, Ohio

  • Integro Theranostics Research Site #5

    Philadelphia, Pennsylvania

  • Integro Theranostics Research Site #3

    Dallas, Texas

  • Integro Theronostics Research Site #1

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.